Research programme: anthracyclines - Galilaeus Oy

Drug Profile

Research programme: anthracyclines - Galilaeus Oy

Alternative Names: Research programme: anticancer therapeutics - Galilaeus Oy/Heidelberg Pharma; S 2512; S 2513

Latest Information Update: 16 Nov 2010

Price : $50

At a glance

  • Originator Galilaeus Oy
  • Developer Heidelberg Pharma
  • Class Anthracyclines
  • Mechanism of Action DNA inhibitors; RNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 15 May 2003 Preclinical trials in Cancer in Finland (unspecified route)
  • 15 May 2003 S 2513 and S 2521 are available for licensing (
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top